We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > atopic dermatitis

News List

Novartis bags rights to Galapagos/MorphoSys atopic dermatitis drug pharmatimes
July 20, 2018
Novartis has signed an exclusive global license agreement with Galapagos and MorphoSys for MOR106, a novel antibody directed against IL-17C.
Atopic dermatitis patients to be denied NHS access to Dupixent pharmatimes
July 19, 2018
The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
Lilly/Incyte's baricitinib musters mixed data in atopic dermatitis trial fiercebiotech
September 18, 2017
In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective, prompting unfavorable comparisons with Sanofi and Regeneron's recently approved Dupixent.

Previous page 1 2 3 4 Next page